CD123 is the α-subunit of the interleukin-3 receptor; it represents a potential therapeutic target in systemic mastocytosis (SM) given its absent expression on normal/reactive mast cells (MCs) and ...
Currently, the most powerful independent prognostic factor for progression-free survival (PFS) among ISM patients relies on the presence of multilineage involvement of myeloid or myeloid plus lymphoid ...